All In Biotech

Free tool

FAERS Monitor: Cervidil

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020411 or its brand name (Cervidil, Dinoprostone). Reports on generic versions are filed under their own applications.

Reports

769

Serious

660

86% of reports

Hospitalization

202

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • foetal exposure during pregnancy127
  • drug exposure during pregnancy70
  • exposure during pregnancy70
  • caesarean section63
  • maternal exposure during pregnancy58
  • premature separation of placenta47
  • off label use44
  • uterine hyperstimulation41
  • drug ineffective36
  • premature baby35
  • haemoglobin decreased33
  • premature delivery33
  • white matter lesion30
  • uterine hypertonus28
  • hypospadias26

Reports by year received

View as table
YearReports
20049
20058
200624
200710
200829
20099
20105
201118
201215
201321
201413
201518
201636
201750
201858
201939
202046
202154
202266
202395
202454
202554
202638

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,390 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
uterine hyperstimulationSignal4118401.412465.5440,210
uterine hypertonusSignal283154.62147.276,351
premature separation of placentaSignal47861.9650.338,352
white matter lesionSignal30665.6466.618,793
hypospadiasSignal26346.2236.78,501
caesarean sectionSignal63148.7117.39,053
premature deliverySignal3356.840.71,751
drug exposure during pregnancySignal7056.445.13,753
foetal exposure during pregnancySignal12742.836.55,155
premature babySignal3531.823.01,015
exposure during pregnancySignal7030.824.71,995
maternal exposure during pregnancySignal5817.813.9907
haemoglobin decreasedSignal338.86.3221
off label use441.41.04
drug ineffective360.70.53

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.